Home » ETF » FTXH

FTXH - First Trust Nasdaq Pharmaceuticals ETF

Stock Price: $25.96 USD 0.14 (0.52%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Assets $20.65M
NAV $25.82
Expense Ratio 0.60%
PE Ratio 22.71
Beta (5Y) 0.92
Dividend (ttm) $0.23
Dividend Yield 0.89%
Ex-Dividend Date Mar 25, 2021
1-Year Return -
Trading Day April 16
Last Price $25.96
Previous Close $25.83
Change ($) 0.14
Change (%) 0.52%
Day's Open 25.68
Day's Range 25.68 - 25.96
Day's Volume 2,094
52-Week Range 21.16 - 27.08

Fund Description

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Asset Class
Equity
Sector
Large Cap
Region
North America
Inception Date
Sep 20, 2016
Exchange
NASDAQ
Ticker Symbol
FTXH
Index Tracked
Nasdaq US Smart Pharmaceuticals Index

Top 10 Holdings

61.47% of assets
NameSymbolWeight
United TherapeuticsUTHR9.57%
Bristol-Myers SquibbBMY8.34%
Johnson & JohnsonJNJ8.03%
Horizon TherapeuticsHZNP7.35%
AbbVieABBV7.17%
PfizerPFE4.45%
Prestige Consumer HealthcarePBH4.28%
MerckMRK4.19%
Abbott LaboratoriesABT4.10%
Jazz PharmaceuticalsJAZZ3.97%
View All Holdings

Dividends

Ex-DividendAmountPay Date
Mar 25, 2021$0.0771Mar 31, 2021
Dec 24, 2020$0.0644Dec 31, 2020
Sep 24, 2020$0.043Sep 30, 2020
Jun 25, 2020$0.046Jun 30, 2020
Mar 26, 2020$0.0591Mar 31, 2020
Dec 13, 2019$0.0411Dec 31, 2019
Full Dividend History

News

Hide News
  • All
  • Videos
  • Conversation

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other tickers mentioned: FDL, IEIH, IHE
2 weeks ago - Zacks Investment Research

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other tickers mentioned: IHE, PJP, PPH, XPH
2 months ago - Zacks Investment Research

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

Other tickers mentioned: DHS, FDL, HDV, IEIH
3 months ago - Zacks Investment Research

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Other tickers mentioned: PJP, PPH, PSCH, XHS, XPH
5 months ago - Zacks Investment Research

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other tickers mentioned: IHE, PJP, PPH, XPH
5 months ago - Zacks Investment Research

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?

6 months ago - Zacks Investment Research

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other tickers mentioned: IHE, PJP, PPH, XPH
8 months ago - Zacks Investment Research

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

Other tickers mentioned: AZN, GERM, MRNA, NVAX, PFE, PPH, PTH ...
8 months ago - Zacks Investment Research

ETF Spotlight: Pharmaceuticals driven higher by Pfizer

YouTube video

CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.

9 months ago - CNBC Television

Strong results led to solid trading in pharma ETFs over the past week.

Other tickers mentioned: IHE, PJP, PPH, XPH
1 year ago - Zacks Investment Research

Robust results led to solid trading in pharma ETFs in a month.

Other tickers mentioned: IHE, PJP, PPH, XPH
1 year ago - Zacks Investment Research

Despite robust results, pharma ETFs have been trending downward in a month.

Other tickers mentioned: IHE, PJP, PPH, XPH
1 year ago - Zacks Investment Research

Despite such robust results, pharma ETFs have been trending downward in a month.

Other tickers mentioned: IHE, PJP, PPH, XPH
1 year ago - Zacks Investment Research